CSO To Review Progress of Clinical Trials and Vaccine Technology
ATLANTA, GA - April 7, 2011- Harriet Robinson, Ph.D., Chief Scientific Officer
at GeoVax Labs, Inc. (OTCBB:GOVX), will provide an update on the
status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord
National Hotel and Convention Center in Washington DC on Thursday, April 14. Dr. Robinson's invited talk, which will
run from 11:30 - 11:50 a.m., will cover the topic of recombinant viruses as vaccines. The talk will be followed by a
Q&A session at 12:30 pm.
GeoVax has a multi-protein clade B HIV/AIDS vaccine in an open-label Phase 1/2 therapeutic trial
and in a double-blinded, 300-participant Phase 2a preventative trial. The preventative trial is being conducted and
supported by the US HIV Vaccine Trials Network (HVTN). The vaccine was developed in Dr. Robinson's former laboratory
at the Emory Vaccine Center in collaboration with Dr. Bernard Moss's laboratory at the US National Institutes of
Health and researchers at the US Centers for Disease Control and Prevention. Recently, the Company announced a
70% prevention rate in a non-human primate study using their GM-CSF co-expressing vaccine. This represents
the highest successful prevention rate ever achieved in such a non-human model with a preventative vaccine for HIV.
Dr. Robinson, formerly Asa Griggs Candler Professor of Microbiology and Immunology at Emory University
and Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center, is internationally
recognized for her work on HIV/AIDS vaccines, her pioneering studies on the use of recombinant DNA for vaccination and her
seminal studies on insertional mutagenesis and oncogene transduction in retroviral induced cancers. She received her
Ph.D. from the Massachusetts Institute of Technology and her postdoctoral training at the Virus Laboratory,
University of California Berkeley. Dr. Robinson is active on several editorial boards and has consulted
for the US NIH, the US Food and Drug Administration, the World Health Organization, and the Gates Foundation.
The annual World Vaccine Conference, which attracted over 485 delegates in 2010, provides attendees with the opportunity
to hear from North America 's leading governmental stakeholders, business leaders and scientific stakeholders as they continue to enhance
the scientific and strategic innovation behind a burgeoning vaccine industry. For more information about the conference, please
visit: www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm .
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human
Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing
HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under
GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness,
and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in
expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope
glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations
and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic
T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1
testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January
2009 and will ultimately involve 300 participants at sites in the United States and South America.
Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals individuals already
infected with HIV. For more information, please visit www.geovax.com.
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters
involve risks and uncertainties that may cause actual results to differ materially, including the following:
changes in economic conditions; general competitive factors; acceptance of the Company's products in
the market; the Company's success in technology and product development; the Company's ability to
execute its business model and strategic plans; and all the risks and related information described from
time to time in the Company's SEC filings, including the financial statements and related information
contained in the Company's SEC Filing. GeoVax assumes no obligation to update the information in this
The Investor Relations Group:
Janet Vasquez / Laura Colontrelle
"Reproduced with permission - GeoVax Labs, Inc."
GeoVax Labs, Inc.